Login to Your Account

Pozen's Migraine Treatment Positive In Second Phase III

By Randall Osborne

Monday, October 7, 2002
Pozen Inc.'s injected migraine drug, MT300, achieved its primary endpoint - sustained relief of pain - in its second pivotal trial and, although the drug did not do as well meeting secondary endpoints during the two hours after dosing, it showed statistical significance in providing relief of those symptoms on a sustained basis. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription